Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Osteoporosis

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

Bone.

Tsourdi E, Makras P, Rachner TD, Polyzos S, Rauner M, Mandanas S, Hofbauer LC, Anastasilakis AD

doi: 10.1016/j.bone.

Osteoporosis

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis

Clin Interv Aging.

Mederle OA, Balas M, Ioanoviciu SD, Gurban CV, Tudor A, Borza C

doi: 10.2147/CIA.S170111.

Osteoporosis

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Ann Intern Med.

Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians

doi: 10.7326/M15-1361.

Osteoporosis

Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment

Bone.

Butscheidt S, Rolvien T, Vettorazzi E, Frieling I

doi: 10.1016/j.bone.2018.06.022.

Osteoporosis

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Lancet Diabetes Endocrinol.

McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.

doi: 10.1016/S2213-8587(19)30346-8.

Osteoporosis

Abaloparatide for the treatment of postmenopausal osteoporosis

Drugs Today (Barc).

Pietrogrande L, Raimondo E

doi: 10.1358/

Osteoporosis

Screening and Treatment for Osteoporosis After Stroke

Stroke.

Kapoor E, Austin PC, Alibhai SMH, Cheung AM, Cram P, Casaubon LK, Fang J, Porter J, Smith EE, Prager M, Kapral MK

doi: 10.1161/STROKEAHA.

Osteoporosis

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Osteoporos Int.

Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C

doi: 10.1007/s00198-018-4794-0.

Osteoarthritis

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

Lancet Diabetes Endocrinol.

Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML, Foundation for the National Institutes of Health Bone Quality Project

doi: 10.

Related content

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Abaloparatide for the treatment of postmenopausal osteoporosis

Screening and Treatment for Osteoporosis After Stroke

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials